Too Much, Too Soon: OPDP Issues Untitled Letter for Pre-approval Promotion

Too Much, Too Soon: OPDP Issues Untitled Letter for Pre-approval Promotion

Source: 
FDA Law Blog
snippet: 

Just as many object to holiday music in November, the Office of Prescription Drug Promotion (“OPDP”) objected in an untitled letter issued earlier this month to claims made for an investigational drug.  The statements (since removed) appeared on a company website about an investigational drug for the treatment of brain cancer.